LXEO (LXEO) Stock Analysis
Verdict: AVOID
Pre-revenue gene therapy burn puts cash runway under 8 months, creating heavy dilution risk despite broad Wall Street buy ratings.
Investment score: 35/100
The model views LXEO as a high-risk clinical-stage biotech asset facing acute cash runway pressures that outweigh optimistic analyst price targets.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| DMAC | -9.53 | 9.64 | 0.00 | -9.83 | — | 0.00 |
| MYGN | -3.37 | 1.26 | 0.47 | -10.53 | — | -0.14 |
| ZNTL | -1.25 | 1.51 | 0.00 | -1.34 | — | 0.00 |
| EBS | -2.04 | 1.06 | 0.47 | -33.94 | — | -0.23 |
| EVMN | -3.38 | 1.25 | 34.73 | -3.08 | — | -9.47 |